To the Editor Although Dr Jones and colleagues1 claimed that the FDA regards “Preventing prescription opioid deaths [as] a public health priority,” this is not consistent with the FDA’s behavior. For example, the FDA instituted the untested, class-wide Risk Evaluation and Mitigation Strategy (REMS) program but continued to approve new extended release/long-acting (ER/LA) opioids with no evidence that the REMS actually reduces ER/LA opioid-related morbidity.
Busch DA. Preventing Prescription Opioid Abuse. JAMA. 2015;313(10):1059–1060. doi:10.1001/jama.2015.0518
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: